Thursday, February 1, 2024

Covid 19 Publications

 1. Kannan, M., Sathiyarajeswaran, P., Sasikumar, D., Geetha, A., Mohanapriya, M., Vinod, N. P., Manickam, P., Kanakavalli, K., Parthibhan, P., Pitchiah Kumar, M., Kannan, R., & Sivaraman, G. (2022). Safety and efficacy of a Siddha Medicine fixed regimen for the treatment of asymptomatic and mild COVID-19 patients. Journal of Ayurveda and integrative medicine13(3), 100589. https://doi.org/10.1016/j.jaim.2022.100589.

2. Natarajan, S., Anbarasi, C., Sathiyarajeswaran, P., Manickam, P., Geetha, S., Kathiravan, R., Prathiba, P., Pitchiahkumar, M., Parthiban, P., Kanakavalli, K., & Balaji, P. (2021). Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India. Trials22(1), 623. https://doi.org/10.1186/s13063-021-05583-0.


3.Gangarapu Kiran, L. Karthik, M.S. Shree Devi, P. Sathiyarajeswaran, K. Kanakavalli, K.M. Kumar, D. Ramesh Kumar,In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein,Journal of Ayurveda and Integrative Medicine,Volume 13, Issue 1,2022,100324,ISSN 0975-9476,https://doi.org/10.1016/j.jaim.2020.05.009(https://www.sciencedirect.com/science/article/pii/S0975947620300243)

4.MS, Shree Devi and MS, Shree Devi and MS, Shree Devi and P, Sathiyarajeswaran and L, Karthik and K., Kanakavalli and S., Chandru and Singh, Nipendra, In vitro Antiviral Activity of Kabasura Kudineer - Siddha Polyherbal Formulation Against Novel Coronavirus (SARS-CoV-2) (May 8, 2021). Available at SSRN: https://ssrn.com/abstract=3842077 or http://dx.doi.org/10.2139/ssrn.3842077



for more click below link of CCRS

https://siddhacouncil.com/ccrs/wp-content/uploads/2022/01/CCRS_COVID-19_PUBLICATIONS_UPDATED_04012022.pdf


No comments: